The era of the simple chatbot is over. The new wave of AI tools doesn't just answer questions—they execute entire projects.

As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...

Global Limited (“Tiger Brokers (Hong Kong)”) is proud to announce its inaugural sponsorship of the 2025–2026 CFA Institute ...

At the fence line of the Pearl Street tank farm, benzene levels were higher than the state’s ambient average guideline. But ...

The proportion of women presenting to Australian general practice with endometriosis almost doubled between 2011‒2021, according to a new study by ...

An announcement from UltraTech Cement Limited ( ($IN:ULTRACEMCO) ) is now available. UltraTech Cement Limited has updated its investor ...

A JCPS Revenue Advisory Task Force member is questioning the entity's purpose following Superintendent Yearwood's statements ...

Patients in cohort 9 received enfortumab vedotin at 1.25 mg/kg intravenously on days 1 and 8 plus pembrolizumab at 200 mg intravenously on day 1 of each 21-day cycle. Treatment was administered until ...

On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...

Rehman Sobhan said that although around 4–5% of Bangladesh’s development budget is allocated to climate-related programmes, “we still lack sufficient analysis on how effectively those allocations are ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...